New Delhi, Oct. 15 -- Novo Nordisk, a Danish multinational pharmaceutical company, has expressed support for India's mission to eliminate sickle cell disease by 2047, highlighting the need for early diagnosis, public awareness, better healthcare infrastructure and improved access to treatment.

Sickle cell disease (SCD) is a chronic single gene disorder causing a debilitating systemic syndrome characterized by chronic anemia, acute painful episodes, organ infarction and chronic organ damage and by a significant reduction in life expectancy.

Habib Bennaceur, Senior Vice President of the Rare Disease Unit at Novo Nordisk, said India accounts for a significant share of the global sickle cell disease burden, with around 10 million people liv...